Tamoxifen: what it treats, how to take it, side effects
Last updated September 3, 2026.
Tamoxifen is the original estrogen-blocking breast cancer drug: a daily tablet, taken for 5 to 10 years, that cuts recurrence in hormone-receptor-positive disease and can prevent breast cancer in high-risk women. It is a SERM, blocking estrogen in breast tissue while acting like weak estrogen in bone and the uterus, which explains both its benefits and its boxed warnings.
What does it treat?
Hormone-receptor-positive breast cancer after surgery (cutting recurrence and death rates over decades of data), metastatic disease, DCIS after treatment, and prevention in women at high risk. In treatment settings, 5 years is the floor and 10 years shows additional benefit in the extended trials, which is why oncologists quote a decade now.
How do you take it?
Once or twice daily (20 mg is the common dose) with or without food, at the same time each day, for years: the benefits compound with duration and vanish with early stopping. Missed dose: take it when remembered unless the next is near; never double up. Premenopausal women must use nonhormonal contraception, because tamoxifen can harm a pregnancy, and the no-pregnancy window extends 2 months past the last dose. Annual gynecologic exams are part of the deal because of the uterine-cancer warning.
Side effects to know
- Common: hot flashes and night sweats (the most common complaint, sometimes fierce), vaginal discharge or dryness, mood changes, fatigue, and weight drift.
- Serious (boxed warnings): uterine cancer (roughly 2 to 3 times the background rate, which is why any abnormal bleeding is reported immediately), blood clots and pulmonary embolism, and stroke. Cataracts and other eye changes occur; vision changes get reported. Bone: it protects density after menopause but can thin it before.
Who should not take it?
Not with a history of blood clots or stroke, and not alongside warfarin-type anticoagulation in the prevention setting. Pregnancy is contraindicated. Some antidepressants (paroxetine and fluoxetine especially) block the enzyme that activates tamoxifen, so the antidepressant list gets reviewed. High-risk smokers with clot histories are prevention-settting cautions. The risk-benefit is computed individually, which is why the "high risk" prevention criteria exist.
When is it an emergency?
Call 911 for leg swelling with pain, sudden breathlessness or chest pain, one-sided weakness or slurred speech, or sudden vision loss. Any vaginal bleeding after menopause is a call-this-week symptom, not a watch-and-wait. Pymander's escalation routing is built and tested specifically for this class of decision; see the safety architecture working paper.
What a Pymander AI doctor consult looks like
Illustrative example, not a real member's messages.
Common questions
Ten years is a long time. Is it really worth it?
The extended trials (ATLAS and aTTom) compared 10 years to 5 and found the extra years keep reducing recurrence and breast-cancer deaths, with the protection building in the second decade, after stopping. For ER-positive disease it remains one of the most consequential decisions in the whole treatment plan, which is why oncologists push through the side-effect management rather than shrug at quitting.
How bad are the hot flashes, really?
The most common complaint, ranging from mild warmth to drenching night sweats, worst in the first year and fading for many. Management that actually helps: layered clothing, cool sleep environments, avoiding triggers like spicy food and alcohol, and for severe cases, non-hormonal drugs like venlafaxine or gabapentin. What you cannot use is estrogen, which defeats the whole point.
What is the uterine cancer risk, in plain numbers?
Roughly 2 to 3 times the background rate, which in absolute terms means a few extra cases per thousand women per year, concentrated in postmenopausal women. The defense is simple and effective: any abnormal vaginal bleeding or spotting gets reported immediately and checked, because caught early it is highly treatable. Annual gynecologic exams continue throughout.
Which antidepressants clash with it?
The strong CYP2D6 inhibitors, paroxetine and fluoxetine chiefly, block the enzyme that converts tamoxifen into its active form, potentially blunting the cancer benefit. Safer companions include venlafaxine, citalopram, and escitalopram. The full medication list, including over-the-counter supplements, goes through the oncology pharmacist once, at the start.
Does it cause weight gain?
The trials say no consistent effect; menopause itself and reduced activity during treatment years do the gaining. Blaming the tablet is human nature, but the honest answer is that the weight-management work during these years is the same unglamorous work as ever.
What happens if I just stop early?
Recurrence risk returns toward what it would have been untreated, because the benefit is duration-dependent. If side effects are driving the thought, that is a side-effect-management conversation first, since most tolerability problems have real fixes. Switching to an aromatase inhibitor (for postmenopausal women) is the structured alternative, not stopping into the wind.